Astilbin prevents osteoarthritis development through the TLR4/MD-2 pathway

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• Osteoarthritis (OA) is a leading cause of disability in the elderly, characterized by joint inflammation.
• Astilbin, a natural compound from plants like Hypericum perforatum, has known antioxidant and anti-inflammatory properties.
• No prior studies have investigated Astilbin's protective effects against OA.

Purpose of the Study:

• To investigate the therapeutic potential of Astilbin in human OA chondrocytes and a mouse model of OA.
• To elucidate the molecular mechanisms underlying Astilbin's effects on inflammation and matrix degradation in OA.

Main Methods:

• In vitro studies used human OA chondrocytes treated with lipopolysaccharide (LPS).
• In vivo studies utilized a mouse model of osteoarthritis induced by destabilization of the medial meniscus (DMM).
• Assessed inflammatory cytokine production, enzyme expression, extracellular matrix degradation, and TLR4/NF-κB signaling pathway activation.

Main Results:

• Astilbin inhibited LPS-induced production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6).
• Astilbin suppressed the overexpression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).
• Astilbin prevented extracellular matrix degradation by down-regulating MMP13 and ADAMTS5, and inhibited the TLR4/NF-κB pathway.

Conclusions:

• Astilbin exhibits significant chondroprotective effects in both in vitro and in vivo models of osteoarthritis.
• Astilbin acts by inhibiting key inflammatory mediators and matrix-degrading enzymes.
• Astilbin demonstrates potential as a novel therapeutic agent for osteoarthritis treatment.